心脏手术后起搏器植入的当代全国性视角
术后 30 天、1 年和 10 年累积发生率分别为 2.9%、3.8% 和 9.5%,主要适应证为房室传导阻滞;三尖瓣手术风险最高,合并手术和同期消融进一步增加风险。
要点
- 心脏术后永久起搏器植入需求显著,10 年累积发生率达 9.5%。
- 三尖瓣手术在孤立手术中起搏器风险最高,30 天达 6.8%。
- 同期外科消融显著增加起搏器植入风险(校正 HR 9.2)。
核心结论
- 心脏手术后永久起搏器植入需求可观,主要适应证为房室传导阻滞。
- 三尖瓣手术在孤立手术中起搏器风险最高,合并手术和同期消融进一步增加风险。
研究设计与样本
- 排除既往起搏器、既往或后续植入式心律转复除颤器(ICD)及心脏移植患者。
主要发现
- 总体 8.2%(n=6271)接受永久起搏器植入。
- 术后 30 天、1 年和 10 年累积发生率分别为 2.9%、3.8% 和 9.5%。
- 三尖瓣手术 30 天累积发生率 6.8%(95%CI 4.3%–10.0%),1 年 8.8%(95%CI 6.0%–12.0%)。
- 二尖瓣手术 30 天 5.3%(95%CI 4.7%–6.0%),1 年 6.5%(95%CI 5.8%–7.3%)。
- 主动脉瓣手术 30 天 4.8%(95%CI 4.5%–5.1%),1 年 6.0%(95%CI 5.6%–6.3%)。
关键数值与推荐
- 冠状动脉旁路移植术 30 天累积发生率 0.74%(95%CI 0.6%–0.8%),1 年 1.3%(95%CI 1.2%–1.3%)。
- 联合手术(多瓣膜和/或冠状动脉旁路移植术)30 天 6.5%(95%CI 6.0%–6.9%),1 年 8.1%(95%CI 7.7%–8.6%)。
- 同期消融手术增加起搏器植入风险(校正 HR 9.2,95%CI 7.9–10.6;p<0.001)。
临床怎么用
- 心脏术后应关注房室传导阻滞,尤其三尖瓣手术、联合手术及同期消融患者。
- 术后 30 天内及 1 年内需监测起搏器植入指征,长期随访亦不可忽视。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiac surgery carries a heightened risk of bradyarrhythmias, but current permanent pacemaker (PPM) implantation estimates rely on non-contemporary studies. This study primarily aimed to explore the incidence and indications for PPM implantation at 30 days and 1 year after different cardiac surgical procedures in a modern cohort. Secondary outcomes were PPM incidence at 10 years and time from cardiac surgery to PPM implantation. METHODS: This nationwide population-based study included all patients in Sweden who from 2006 to 2020 underwent first-time coronary artery bypass grafting (CABG) and/or valvular surgery. Patients with previous PPM, previous or later implantable cardioverter-defibrillator (ICD) and those who underwent heart transplantation were excluded. RESULTS: Overall, 76 447 patients were included, out of which 8.2% (n=6271) received a PPM. The cumulative incidence of PPM implantation was 2.9%, 3.8% and 9.5% at 30 days, 1 year and 10 years following cardiac surgery, respectively. The main PPM indication was atrioventricular block. Tricuspid valve surgery exhibited the highest cumulative incidence for PPM both at 30 days (6.8%, 95% CI 4.3% to 10.0%) and 1 year (8.8%, 95% CI 6.0% to 12.0%) surpassing mitral valve surgery (30 day 5.3%, 95% CI 4.7% to 6.0%; 1 year 6.5%, 95% CI 5.8% to 7.3%), aortic valve surgery (30 day 4.8%, 95% CI 4.5% to 5.1%; 1 year 6.0%, 95% CI 5.6% to 6.3%) and CABG (30 day 0.74%, 95% CI 0.6% to 0.8%; 1 year 1.3%, 95% CI 1.2% to 1.3%). The incidence following combined operations (multiple valves and/or CABG) was 6.5% (95% CI 6.0% to 6.9%) and 8.1% (95% CI 7.7% to 8.6%) at 30 days and 1 year, respectively. Concomitant ablation surgery increased the risk even further (adjusted HR 9.2, 95% CI 7.9 to 10.6; p<0.001). CONCLUSIONS: The need for PPM after cardiac surgery is substantial, primarily due to atrioventricular block. Tricuspid valve surgery is associated with the highest risk for PPM among isolated procedures. Combined procedures and concomitant surgical ablation further increase that risk.
引用
- Taha A, David A, Ragnarsson S, et al. Pacemaker implantation after cardiac surgery: a contemporary, nationwide perspective. Heart. 2025. PMID: 40157746. doi:10.1136/heartjnl-2024-325321
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。